Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection (Onco-VOC)
Bronchopulmonary cancer, with 39 000 new cases and 30 000 deaths per year, is a main issue in public health in France. It is the leading cause of cancer death in France. A lot of progress in medical care has been made, but surgery remains the most effective treatment, when it is still possible. The goal is to detect and manage the lung cancer as early as possible. Alongside screening strategies by annual thoracic scanner, new approaches with innovative technologies open up for cancer detection and therapeutic follow-up.
The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases.
The composition of VOC in exhaled air and sweat is altered in patients with lung cancer. The VOC analysis and their variation could be used particularly in the follow-up of patients treated for lung cancer.
The purpose of this clinical research is to identify the VOCs related to lung cancers by comparing the VOC profiles in exhaled air and in sweat from patients diagnosed with localized lung cancer before and after resection surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Elisabeth Hullier-Ammar
- Phone Number: +33 1 46 25 11 75
- Email: drci-promotion@hopital-foch.com
Study Locations
-
-
-
Suresnes, France, 92150
- Recruiting
- Hôpital Foch
-
Contact:
- Philippe Devillier
- Phone Number: 33 1 46 25 27 91
- Email: p.devillier@hopital-foch.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient aged ≥ 18 years old
- Patient with non-small cell lung cancer
- Operable grade I or II
- No specific treatment before surgery (radiotherapy, chemotherapy or targeted therapy)
- Patient with healthcare insurance
Non Inclusion Criteria:
- Treatment with radiotherapy, chemotherapy, or neoadjuvant cancer targeted therapy before thoracic surgery
- Patient with oxygen therapy or invasive ventilation
- Patient unable to perform a slow vital capacity
- Dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance)
- Pregnant women
- Patient deprived of liberty by judicial or administrative decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: VOC analysis
VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
|
VOC analysis in exhaled air with e-noses and mass spectrometry
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Volatil Organic Compound (VOC) profiles by mass spectrometry
Time Frame: change from baseline profiles at 2 month post-surgery
|
Comparison of variation in Volatil Organic Compound (VOC) profiles in exhaled air of patients before and after surgery.
The VOC will be identified by their molecular mass (by the mass spectrometry)
|
change from baseline profiles at 2 month post-surgery
|
|
Comparison of Volatil Organic Compound (VOC) profiles in by electronic noses
Time Frame: change from baseline profiles at 2 month post-surgery
|
Comparison of variation in Volatil Organic Compound (VOC) profiles in exhaled air of patients before and after surgery.
The VOC will be identified by the sensor deflection (by the electronic noses).
|
change from baseline profiles at 2 month post-surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Volatil Organic Compound (VOC) profiles in sweat
Time Frame: 30 days before the surgery and 45 to 75 days after surgery
|
Comparison of Volatil Organic Compound (VOC) profiles in sweat of patients before and after surgery.
The VOC will be identified by their molecular mass (by the mass spectrometry).
|
30 days before the surgery and 45 to 75 days after surgery
|
|
Variation of Volatil Organic Compound (VOC) and relapse rate
Time Frame: 30 days before the surgery, 45 to 75 days after surgery and 2 years
|
Correlation between the variation of Volatil Organic Compound (VOC) before-after surgery and relapse rate at 2 years
|
30 days before the surgery, 45 to 75 days after surgery and 2 years
|
|
Correlation between Volatil Organic Compound (VOC) profiles and relapse rate
Time Frame: 2 months and 2 years after surgery
|
Correlation between the Volatil Organic Compound (VOC) profiles 2 months after the surgery and relapse rate at 2 years
|
2 months and 2 years after surgery
|
|
Comparison of Volatil Organic Compound (VOC) profiles in exhaled air and tumoral lung tissue
Time Frame: 30 days before the surgery, day of surgery and 45 to 75 days after surgery
|
Comparison of Volatil Organic Compound (VOC) profiles in exhaled air of patients and those released ex-vivo by the tumoral lung tissue.
The VOC will be identified by their molecular mass (by the mass spectrometry).
|
30 days before the surgery, day of surgery and 45 to 75 days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017081
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.